Item Type | Name |
Academic Article
|
Hyperlipidemia following heart transplantation: natural history and intervention with mevinolin (lovastatin).
|
Academic Article
|
Low-density lipoprotein metabolism in cerebrotendinous xanthomatosis.
|
Academic Article
|
Degree of HLA mismatch as a predictor of death from allograft arteriopathy after heart transplant.
|
Academic Article
|
Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis.
|
Academic Article
|
Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins.
|
Academic Article
|
Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S.
|
Academic Article
|
Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study.
|
Academic Article
|
Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
|
Academic Article
|
Characteristics of US adults with the metabolic syndrome and therapeutic implications.
|
Academic Article
|
Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia.
|
Academic Article
|
Lipoprotein(a) and apolipoprotein changes after cardiac transplantation.
|
Academic Article
|
Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome.
|
Academic Article
|
Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome.
|
Academic Article
|
Combination therapy for combined dyslipidemia.
|
Academic Article
|
Effects of PPARalpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study.
|
Academic Article
|
Marine omega-3 fatty acid intake: associations with cardiometabolic risk and response to weight loss intervention in the Look AHEAD (Action for Health in Diabetes) study.
|
Academic Article
|
Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction.
|
Academic Article
|
Biological, clinical and population relevance of 95 loci for blood lipids.
|
Academic Article
|
Relationship between low-density lipoprotein subclasses and asymptomatic atherosclerosis in subjects from the Atherosclerosis Risk in Communities (ARIC) Study.
|
Academic Article
|
Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association.
|
Academic Article
|
Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial.
|
Academic Article
|
Barriers to non-HDL cholesterol goal attainment by providers.
|
Academic Article
|
A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis.
|
Academic Article
|
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci.
|
Academic Article
|
Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).
|
Academic Article
|
Authors' reply.
|
Academic Article
|
Effects of cyclosporine therapy on plasma lipoprotein levels.
|
Academic Article
|
Longitudinal impact of physical activity on lipid profiles in middle-aged adults: the Atherosclerosis Risk in Communities Study.
|
Academic Article
|
CD11c/CD18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1.
|
Academic Article
|
Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.
|
Academic Article
|
Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.
|
Academic Article
|
Relation of lipid gene scores to longitudinal trends in lipid levels and incidence of abnormal lipid levels among individuals of European ancestry: the Atherosclerosis Risk in Communities (ARIC) study.
|
Academic Article
|
Trans-ethnic fine-mapping of lipid loci identifies population-specific signals and allelic heterogeneity that increases the trait variance explained.
|
Academic Article
|
Effects of dalcetrapib in patients with a recent acute coronary syndrome.
|
Academic Article
|
Non-high-density lipoprotein cholesterol reporting and goal attainment in primary care.
|
Academic Article
|
Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy.
|
Academic Article
|
Effect of moderate alcohol consumption on hypertriglyceridemia: a study in the fasting state.
|
Academic Article
|
Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients.
|
Academic Article
|
Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy.
|
Academic Article
|
Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.
|
Academic Article
|
Increased myocardial susceptibility to repetitive ischemia with high-fat diet-induced obesity.
|
Academic Article
|
Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
|
Academic Article
|
Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.
|
Academic Article
|
Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (= 2 mg/L). cmb@bcm.tmc.edu.
|
Academic Article
|
LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.
|
Concept
|
Triglycerides
|
Academic Article
|
Do genetic modifiers of high-density lipoprotein cholesterol and triglyceride levels also modify their response to a lifestyle intervention in the setting of obesity and type-2 diabetes mellitus?: The Action for Health in Diabetes (Look AHEAD) study.
|
Academic Article
|
The editor's roundtable: hypertriglyceridemia.
|
Academic Article
|
APOE modulates the correlation between triglycerides, cholesterol, and CHD through pleiotropy, and gene-by-gene interactions.
|
Academic Article
|
Elevated plasma SPARC levels are associated with insulin resistance, dyslipidemia, and inflammation in gestational diabetes mellitus.
|
Academic Article
|
The impact of rapid weight loss on oxidative stress markers and the expression of the metabolic syndrome in obese individuals.
|
Academic Article
|
Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia.
|
Academic Article
|
Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST).
|
Academic Article
|
Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.
|
Academic Article
|
Low-density lipoprotein electronegativity is a novel cardiometabolic risk factor.
|
Academic Article
|
Inactivating mutations in NPC1L1 and protection from coronary heart disease.
|
Academic Article
|
Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study).
|
Academic Article
|
Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk.
|
Academic Article
|
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies.
|
Academic Article
|
Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies.
|
Academic Article
|
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
|
Academic Article
|
Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome.
|
Academic Article
|
Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials).
|
Academic Article
|
Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.
|
Academic Article
|
Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial.
|
Academic Article
|
Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease.
|
Academic Article
|
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
|
Grant
|
Genetics and Personalized Medicine: From Population Studies to Clinical Therapy
|
Grant
|
COMMUNITY AND COHORT SURVEILLANCE PROGRAM
|
Academic Article
|
Multiancestry Genome-Wide Association Study of Lipid Levels Incorporating Gene-Alcohol Interactions.
|
Academic Article
|
Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study.
|
Academic Article
|
Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides.
|
Academic Article
|
Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles.
|
Academic Article
|
Reply: Ischemic Event Reduction and Triglycerides.
|
Academic Article
|
Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions.
|
Academic Article
|
Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.
|
Academic Article
|
Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation.
|
Academic Article
|
Conventional and Novel Lipid Measures and Risk of Peripheral Artery Disease.
|
Academic Article
|
Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study.
|
Academic Article
|
Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk.
|
Academic Article
|
A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study.
|
Academic Article
|
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI.
|
Academic Article
|
Genetic Testing for Hypertriglyceridemia in Academic Lipid Clinics: Implications for Precision Medicine-Brief Report.
|
Academic Article
|
Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial.
|
Academic Article
|
Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia.
|
Academic Article
|
Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial.
|